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The correct interpretation ofmicrobial sequencing data applied to surveillance and outbreak investigation depends on acces-
sible genomic databases to provide vital genetic context. Our aim was to construct and describe a United Kingdom MRSA
database containing over 1000 methicillin-resistant Staphylococcus aureus (MRSA) genomes drawn from England, Northern
Ireland, Wales, Scotland, and the Republic of Ireland over a decade. We sequenced 1013 MRSA submitted to the British
Society for Antimicrobial Chemotherapy by 46 laboratories between 2001 and 2010. Each isolate was assigned to a regional
healthcare referral network in England andwas otherwise grouped based on country of origin. Phylogenetic reconstructions
were used to contextualizeMRSAoutbreak investigations and to detect the spread of resistance. Themajority of isolates (n =
783, 77%) belonged to CC22, which contains the dominantUnitedKingdom epidemic clone (EMRSA-15). Therewasmarked
geographic structuring of EMRSA-15, consistent with widespread dissemination prior to the sampling decade followed by lo-
cal diversification.TheadditionofMRSAgenomes fromtwooutbreaks andonepseudo-outbreakdemonstrated the certainty
with which outbreaks could be confirmed or refuted.We identified local and regional differences in antibiotic resistance pro-
files, with examples of local expansion, as well as widespread circulation of mobile genetic elements across the bacterial pop-
ulation.Wehave generated a resource for the future surveillance andoutbreak investigation ofMRSA in theUnitedKingdom
and Ireland and have shown the value of this during outbreak investigation and tracking of antimicrobial resistance.
[Supplemental material is available for this article.]
Methicillin-resistant Staphylococcus aureus (MRSA) was first isolat-
ed in 1961 in the United Kingdom (UK), 1 yr after methicillin
was introduced into clinical practice (Jevons 1961). The prevalence
of MRSA gradually increased thereafter, and by 1971, 5% of S. au-
reus isolates referred to the National Staphylococcal Reference
Laboratory were MRSA (Marples and Reith 1992). Outbreaks of
gentamicin-resistant MRSA in several hospitals during the late
1970s (Shanson 1981) were followed by the emergence of MRSA
with potential for epidemic spread (Johnson et al. 2005). By the
mid-1980s, MRSA had spread across the UK, and the majority
were epidemic (E)MRSA-1, later assigned as sequence type (ST)
239 by multilocus sequence typing (MLST) (Kerr et al. 1990;
Johnson et al. 2005). A decline in EMRSA-1 in the late 1980s and
early 1990s was associated with an increase in EMRSA-3 (ST 5)
(Marples and Reith 1992; Richardson and Reith 1993; Cox et al.
1995; Enright et al. 2002). This dynamic process continued with
the emergence in the early 1990s of EMRSA-15 (ST 22) and
EMRSA-16 (ST 36) (Richardson and Reith 1993; Cox et al. 1995;
Enright et al. 2002), which disseminated across the UK. These
two clones continue to predominate, with EMRSA-15 accounting
for ∼85% of MRSA bloodstream infections in the UK in 2007
and with trends suggesting that EMRSA-16 is in decline
(Ellington et al. 2010; McAdam et al. 2012). Antimicrobial resis-
tance is known to differ between EMRSA-15 and -16, with
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EMRSA-16 being the more resistant lineage of the two. However,
for both lineages, the acquisition of the SCCmec element confer-
ring methicillin resistance and the presence of mutations in gyrA
and grlA conferring fluoroquinolone resistance are considered to
be major contributors to the success of these epidemic lineages
(Knight et al. 2012; McAdam et al. 2012; Holden et al. 2013).
Bacterial genotyping using pulsed-field gel electrophoresis
(PFGE), MLST, and spa typing has been used to identify epidemic
clones and to give insights into the microevolutionary dynamics
of predominant MRSA lineages in the UK. However, these meth-
ods have limited resolution and lack discriminatory power when
one or a small number of clones predominate (McAdam et al.
2012; Miller et al. 2014; Bartels et al. 2015). This means that
once widely established, the subsequent dynamics of clonal
MRSA spread within and between healthcare facilities cannot be
fully elucidated. As a result, bacterial typing does not form a central
component of MRSA transmission and outbreak investigation.
Several recent publications have confirmed the ability of whole-ge-
nome sequencing (WGS) to define transmission dynamics of a sin-
gle clone at different geographic and temporal scales. This has
identified global and local transmission routes and, when com-
bined with epidemiological data, can confirm or refute putative
MRSA outbreaks (Köser et al. 2012; Harris et al. 2013; Nubel et al.
2013; Miller et al. 2014; Török et al. 2014; Bartels et al. 2015).
Similarly, while surveillance of MRSA has been carried over several
years and a limited number of point prevalence studies of variable
methodology have been undertaken in different settings, serial
systematic prevalence studies of individual epidemic lineages are
lacking (Johnson et al. 2012; Afshinnekoo et al. 2015; Bartels
et al. 2015; Peng et al. 2015).WGS could potentially be used for na-
tional and local surveillance of MRSA lineages and to enhance the
investigation of suspected outbreaks, but comprehensive genomic
databases are required to provide the context that would allow ro-
bust epidemiological interferences. Here, we describe the analysis
of over 1000 MRSA genomes drawn from across the UK and
Ireland over a period of a decade and the first evaluation of this
rich data set to describe the macroepidemiology of MRSA.
Results
Sampling framework for MRSA genome database
Our first objective was to define the population structure and dy-
namics of MRSA across England, Northern Ireland, Wales,
Scotland (together making up the UK), and the Republic of
Ireland over the last decade usingWGS. This was achieved by part-
nering with the British Society for Antimicrobial Chemotherapy
(BSAC), which coordinates an antimicrobial resistance surveil-
lance project across this geographical area (for details, see www.
bsacsurv.org) (Reynolds et al. 2008). The sampling framework is
systematic and unbiased since diagnostic microbiology laborato-
ries submit a defined number of consecutive but nonduplicate S.
aureus isolated from blood cultures each year. A total of 47 centers
contributed S. aureus bacteremia isolates to the BSAC Bacteremia
Resistance Surveillance Program between 2001 and 2010, 24–25
centers each year from 2001–2009, and 38 in 2010 when the net-
work was expanded. Sixteen centers contributed in all 10 yr; 13
contributed only in 2010. The BSAC target was to receive 10 S. au-
reus isolates per center per year in 2001–2007, 20 in 2008–2009,
and 14 in 2010. Actual collections were 97% of target on average,
and <5% of 261 center-year collections were <90% complete.
MRSA bacteremia isolates were confirmed and sequenced from
the 45 laboratories between 2001 and 2010, the geographic loca-
tions of which are shown in Figure 1 (for details, see Supplemental
Table S1). The number of MRSA isolates sequenced by year is
shown in Supplemental Figure S1.
Regional healthcare referral networks have been described for
England. These consist of hospitals in geographical proximity that
frequently exchange patients through referrals and are defined by
boundaries beyond which there is a sharp fall in patient move-
ment (Donker et al. 2014). Patient transfer between hospitals is
highly relevant to patterns of MRSA transmission, and so we
placed our phylogenetic analysis in the context of these referral
networks. Each network contained at least one submitting labora-
tory, with some networks containing multiple laboratories (Fig. 1;
Supplemental Table S1). Around 100 MRSA samples were se-
quenced per year, with an average of six isolates per year per net-
work. Published data are not available on referral networks
within Wales, Scotland, Northern Ireland, and the Republic of
Ireland, and these were each treated as single entities for the pur-
poses of the analysis (Fig. 1; Supplemental Table S1).
Overview of the population structure of MRSA in the UK
The frequency of each clonal complex (CC) by year is shown in
Table 1. CCs are STs that share five or more alleles across the seven
loci examined (Cooper and Feil 2004). Themajority of isolates (n =
783, 77%) belonged to CC22, which contains the dominant epi-
demic clone in the UK and Ireland, EMRSA-15. The second most
frequent CC was CC30 (n = 144, 14%), containing the epidemic
Figure 1. Map of laboratories, submitting regions, and referral net-
works. Laboratories submitting isolates to the British Society of
Antimicrobial Chemotherapy collection are shown as a gray dot. Regions
are colored as indicated, and English regions were based on referral net-
works as previously described (Donker et al. 2014).
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clone EMRSA-16 (ST36). Isolates in CC1, CC5, andCC8 eachmade
up between 1% and 3% of the population, with <1% of isolates as-
signed to CC9, -15, -25, -45, -59, and -97, as well as previously un-
defined CCs. Just two isolates were found to belong to the USA300
clone, which is the most dominant MRSA clone in the United
States of America (Uhlemann et al. 2014). Of the isolates submit-
ted, only three CCs—CC22, CC30, and CC5—had been retrieved
continuously in every year of the study period, whereas all
other CCs were found sporadically. These data describe a period
of clonal stability with no evidence for newly emerging lineages.
Subsequent analyses of the MRSA populations were lineage specif-
ic and examined the fine-scale variation within the two major
lineages.
Lineage-specific phylogenetic analyses
Phylogenetic reconstruction based on 21,848 core SNPswithin the
783 CC22 isolates (Supplemental Figs. S2, S3) revealed a tightly re-
lated, hospital-adapted lineage containing EMRSA-15 (ST22-A2)
and its progenitor lineage (non-ST22-A1) and a genetically more
divergent community-associated population (non-ST22-A) as de-
scribed previously (Holden et al. 2013). Thereforewe reconstructed
the phylogeny focusing only on EMRSA-15, which gave 20,488
core SNP sites in 775 isolates (Fig. 2; Supplemental Fig. S4).
Genome-based studies of global clones of MRSA (e.g., ST239
[Harris et al. 2010], ST22 [Holden et al. 2013]) have demonstrated
genetic clustering of isolates according to country/continent of
isolation, and therefore, we hypothesized that EMRSA-15 would
demonstrate geographical clustering in the UK and Ireland. By col-
or-coding each isolate in the phylogeny according to the referral
network, we showed the presence of strong phylogenetic cluster-
ing by referral network (Fig. 2). Based on all internal nodes in
the phylogeny of isolates from England, quantitative analysis re-
vealed that 44.1% of all internal nodes had descendants from
strictly the same referral network, thus clustering within their re-
spective originating network or region. To substantiate this hy-
pothesis, isolates were randomly assigned to referral network
locations. The average of these 1000 permutation tests showed
on average only 3.0% (IQR: 2.4%–3.6%) of isolates clustered
with isolates within their referral network, indicating that the
strong geographic signal is not arbitrary.
Study isolates were drawn from a period of time that post-
dates the dissemination of EMRSA-15 across the UK and Ireland,
and the sequence data generated here are consistent with regional
diversification following widespread dissemination. In some in-
stances, EMRSA-15 appears to have been introduced into a region
on several occasions, as reflected by the existence of several dis-
tinct clades (e.g., in referral networks South-West and North-
Central) (Fig. 2). We also observed that an introduction event
was sometimes followed by this lineage becoming established
and coexisting with other distinct clades, for example, in North-
Central.
A phylogenetic tree based on 4400 core SNP sites for 140
EMRSA-16 (ST36) isolates revealed a similar structure to the
EMRSA-15 (ST22-A) phylogeny. Although EMRSA-16 was more
sparsely populated, it was widely disseminated with evidence of
geographic structuring (Fig. 3), as reported previously (McAdam
et al. 2012). Analysis of less common CCs suggested some cluster-
ing; for example, eight of 12 CC1 isolates were from the South-
West, and 11 of the 28 CC5 isolates were fromWales.
Using the genomic framework to contextualize
outbreaks
Next, we tested the utility of this genetic database for the investi-
gation of suspected MRSA outbreaks. We have described previous-
ly the use ofWGS to both confirm and refute local outbreaks at the
Cambridge University Hospitals NHS Foundation Trust (Köser
et al. 2012; Harris et al. 2013; Török et al. 2014), and we placed
these within the context provided by the national BSAC collec-
tion. The first MRSA outbreak involved seven infants in a single
neonatal intensive care unit (NICU) caused by EMRSA-15, in
which one isolate in the cluster was genetically divergent com-
pared with the other isolates as a result of being a hypermutator
(Köser et al. 2012). The second MRSA outbreak initially involved
a special care baby unit (SCBU), but MRSA was shown through
genetic analysis to have spread to mothers on a post-natal ward,
to 10 patients in the community who developed skin and soft tis-
sue infections, and to a colonized healthcare worker in the SCBU
(Harris et al. 2013). The outbreak MRSA was a novel ST (ST2371),
which is highly related to ST22 (a single locus variant). A third in-
vestigation of four patients with five episodes of MRSA who had
overlapping periods of admission on a hepatology ward showed
that they had been infected by their carriage strain and thus refut-
ed an outbreak on the ward (Török et al. 2014). Placing genomes
from these three investigations into the phylogenetic tree of the
783 CC22 isolates demonstrated striking demarcation for the
two outbreak clusters but scattering throughout the tree for
MRSA from the hepatology pseudo-outbreak. This analysis also
demonstrated that the two outbreaks in units contained within
the same hospital building were caused by phylogenetically dis-
tant lineages (Fig. 4).
Table 1. Number of MRSA isolates in each S. aureus MLST clonal complex (CC) over time
CC1 CC5 CC8 CC9 CC15 CC22 CC25 CC30 CC45 CC59 CC97 Nondefined CC Total No.
2001 4 6 75 18 103
2002 2 2 1 58 1 24 2 1 91
2003 3 6 61 24 1 95
2004 4 3 93 17 117
2005 1 3 76 8 1 89
2006 1 2 1 1 83 1 18 1 108
2007 3 1 75 1 8 1 1 90
2008 2 4 1 2 92 2 14 1 118
2009 2 2 93 7 1 2 107
2010 1 3 6 77 6 1 1 95
Total (n) 12 28 23 1 3 783 5 144 6 2 2 4 1013
Total % 1.2 2.8 2.3 0.1 0.3 77.3 0.5 14.2 0.6 0.2 0.2 0.3
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Determining distribution and spread of resistance
at different regional levels
The database could also be used for the surveillance of antimicro-
bial resistance inMRSA. To test this, wemined the BSAC data set to
illustrate the potential to highlight (1) local expansion of resis-
tance, (2) regional expansion of a specific resistance determinant,
and (3) resistance determinants that aremorewidely disseminated.
Localized emergence of antimicrobial resistance was observed for
isolates in a closely related lineage (pairwise SNP difference of
28–114) belonging to CC5 from a healthcare institution in
Wales, whichwere clearly separate from the rest of theCC5 isolates
(Fig. 5). These 11 isolates all contain the Tn554 transposon encod-
ing ermA for erythromycin and clindamycin resistance, as well as
type II staphylococcal cassette chromosome mec element encod-
ingmethicillin resistance (SCCmec II). Further antibiotic resistance
mutations were apparent in this cluster with the presence of both
grlA and gyrAmutations for fluoroquinolone resistance. Addition-
ally, 10 out of 11 isolates also contained a mutation in dfrA con-
ferring trimethoprim resistance. This extended spectrum of
antibiotic resistance may explain their apparent regional success
in a single healthcare institution.
We noted that EMRSA-15 isolates from the Republic of
Ireland had a higher prevalence of fusidic acid resistance compared
with isolates from the UK (37.5% vs. 10.4%, respectively). A high
prevalence of fusidic acid resistance has been noted previously
for Ireland and Greece (Castanheira et al. 2010). Fusidic acid resis-
tance can be conferred through gene acquisition ( fusB or fusC) or
by chromosomalmutations ( fusA). Genomic analysis readily dem-
onstrated that mutation dominated over gene acquisition as the
basis for resistance (53 vs. four events, respectively) (Fig. 2).
Resistance in Irish isolates arose through a single L461K mutation
in fusA prior to expansion of this clade and can be found in several
contributing centers. Two other Irish clades, found in the same
hospitals over the same time period, only showed sporadic acqui-
sition of resistance as singular, independent events (Fig. 2).
Examples of more widely distributed resistance profiles in-
cluded trimethoprim resistance in EMRSA-15 and gentamicin/
mupirocin resistance in EMRSA-16. Acquisition of gentamicin
(aacA-aphD), mupirocin (ileS-2), erythromycin (ermC), and amino-
glycoside (ant4-1) resistance genes were found to coincide with
each other as well as with plasmid-related genes in EMRSA-16
(Fig. 3). The presence of these clustered genes in several referral
networks (West Midlands, South-East) suggests a number of circu-
lating plasmids in the EMRSA-16 population. Similarly, in EMRSA-
15, acquisition of dfrA was identified to be the genetic basis for
trimethoprim resistance in isolates from Northern Ireland (10 iso-
lates), Scotland (seven isolates), andWestMidlands/North-Central
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Figure 2. Phylogeny of EMRSA-15 and distribution of antibiotic resistance genes. The maximum likelihood tree of ST22-A isolates was based on core
SNPs identified by mapping to the reference ST22 genome HO 5095 0412. The total number of SNP sites present in the core genome alignment in
this lineage was 20,488 SNPs. Branches are labeled with colors of the referral networks as indicated by the legend. Represented is the year of isolation,
as well as the acquisition of fusB or fusC, fusA mutations, acquisition of dfrA, and dfrA mutations, and ermC acquisition as indicated by the legend.
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(four and five isolates, respectively) (Fig. 2). This is consistent
with the carriage of this gene on a mobile genetic element, but
since dfrA was found separately on its own small contig, we can-
not deduce whether it was carried on a plasmid or transposon.
Trimethoprim resistancewas also encoded by chromosomalmuta-
tions in dfrA, with L41F and F99Y being prominent mutations
basal to a number of referral network clusters (Fig. 2).
We also observed that the extent of antibiotic resistancewith-
in a lineage is governed by the mobile element on which it is car-
ried, an example of which is erythromycin resistance. Contrary
to other resistance determinants that appeared to be locally re-
stricted, erythromycin resistance was very unstable within the
EMRSA-15 population. This is likely due to the fact that the resis-
tance determinant ermC is carried on a small 2-kb plasmid, which
is readily lost and gained. In contrast, erythromycin resistance is
ubiquitous in the EMRSA-16 lineage as ermA is carried on transpo-
son Tn554, which stably integrates into the chromosome as part of
the SCCmec II element.
Discussion
This evaluation of over 1000 MRSA genomes representing isolates
from theUK and Republic of Ireland describes the genetic structure
of dominant lineages (EMRSA-15 and EMRSA-16) over the last dec-
ade. Parallels were observed between the dominant epidemic clone
EMRSA-15 and the declining epidemic clone EMRSA-16, including
geographic structuring and clonality. Numerous other MRSA line-
ages were identified at low prevalence, whichmostly lacked specif-
ic phylogenetic structuring and showed no evidence of expansion
over time. There was strong evidence for region-specific subclones
of EMRSA-15, which at a finer level echoes a previous finding of re-
gional and country-specific clustering for this lineage (Holden
et al. 2013). Regional clustering was also observed for EMRSA-
16, as was previously described (McAdam et al. 2012; Miller
et al. 2014). Owing to the lack of network data for Scotland,
Ireland,Wales, and Northern Ireland, it was not possible to under-
take any further regional stratification within these countries.
However, for the English referral network, isolates from a specific
referral network were more likely to cluster with isolates from
the same region than with isolates from a different network. This
could be influenced by the submitting hospitals, since not all hos-
pitals contributed MRSA isolates in every year. The current sam-
pling strategy did, however, achieve good temporal and regional
coverage. We also observed the presence of multiple subclones
within individual referral networks. This is consistent with a mod-
el inwhich the initial UK-wide dissemination of EMRSA-15 includ-
ed several introductions into each location with subsequent local
diversification.
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Figure 3. Phylogeny of EMRSA-16 and distribution of antibiotic resistance genes. Maximum likelihood tree based on core SNPs identified bymapping to
the reference ST36 genomeMRSA252. The total number of SNP sites present in the core genome alignment in this lineagewas 4400 SNP sites. Branches are
labeled with colors of the referral networks as indicated by the legend. Represented is the year of isolation, as well as acquisition of ermA and ermC (eryth-
romycin resistance), ileS-2 (mupirocin resistance), aacA-aphD (aminoglycoside resistance), dfrA and dfrG (trimethoprim resistance), and ant4-1 (aminogly-
coside resistance), as indicated by the legend.
MRSA surveillance in the UK and Ireland
Genome Research 267
www.genome.org
Local and regional structuringwas also observed for antibiotic
resistance determinants, with both epidemic clones showing re-
gional clades with specific antibiotic resistance patterns. Country-
or region-specific antibiotic treatment regimens impact the
evolution of drug resistance. This has been exemplified previously
for clindamycin in EMRSA-15, where Germany shows higher pre-
scription levels than the UK and where resistance levels are signifi-
cantly higher (Holden et al. 2013). Differences in antimicrobial
resistance have also been noted for the USA-300 clone that is suc-
cessful in the United States, with the coexistence of fluoroquino-
lone-resistant and -susceptible lineages (Alam et al. 2015). Here,
we provide evidence for higher levels of resistance to fusidic acid
in Ireland compared with the UK. Antimicrobial prescription pol-
icies or usage may differ between the UK and the Republic of
Ireland, exerting a potential selective pressure leading to higher
prevalence of fusidic acid resistance in Irish isolates. Locally suc-
cessful clones may also differ in antibiotic resistance patterns,
such as the expansion of CC5 isolates in a single healthcare insti-
tution, or distribution of trimethoprim resistance within referral
networks. Wider dissemination of antibiotic resistance determi-
nants can also be facilitated through carriage of multiple plasmids,
as shown by linked gentamicin/mupirocin resistance putatively
carried on plasmids in the EMRSA-16 population. The fluidity of
antimicrobial resistancemarkers such as ermC in EMRSA-15 affects
clinical practice, as the pattern of antimicrobial resistance is often
used during infection control investigations as a proxy to deter-
mine whether isolates are related and therefore might be part of
an outbreak. This was demonstrated during an outbreak on
SCBU, where the ermC plasmid was lost in some patients (Harris
et al. 2013). By looking at a wider range of isolates within geo-
graphically defined regions, it becomes possible to distinguish
between widespread resistance markers and locally emerging
strains, as well as the stability of mobile genetic elements within
a population.
~ 50 SNPs
SCBU
NICU 
P2
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P4
P1
Figure 4. Contextualization of outbreak investigations of CC22 MRSA studied at Cambridge University Hospitals. The maximum likelihood tree was
based on 22,238 core SNPs for the 783 ST22 genomes, together with seven isolates from anMRSA outbreak on a neonatal intensive care unit (NICU, green)
(Köser et al. 2012), 15 isolates from anMRSA outbreak that focused on a special care baby unit (SCBU, orange) but extended to other wards and the com-
munity (Harris et al. 2013), and 42 isolates sequenced as part of anMRSA outbreak investigation on a hepatologyward (nine isolates from four patients with
bacteremia [P1-4; pink filled dots] and the remainder from patients who were MRSA carriers on the same ward during a comparable timeframe [pink open
dots]) (Török et al. 2014).
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This sequence data set has considerable long-term value,
since it provides a genomic framework for the surveillance of
MRSA lineages and tracking of MRSA transmission between refer-
ral networks in the UK, as well as globally circulating lineages like
EMRSA-15. The likely introduction of bacterial genome sequenc-
ing to confirm or refute MRSA outbreaks will need to use such
data as a source of reference genomes and region-specific compar-
ators, and the availability of this data set in public databases will
provide the ability to visualize such comparisons. Equally, it can
also be used to discern differences within regional clones relating
to antibiotic resistance and will provide valuable information on
resistance determinants as well as their horizontal propagation
and targeted patient care.
Methods
Isolates, sequencing, and analysis
A total of 1013 MRSA isolates were provided by the BSAC bactere-
mia resistance surveillance program (Reynolds et al. 2008) from
2001–2010 (Supplemental Table S2; www.bsacsurv.org). DNA ex-
traction was carried out on a QIAxtractor (Qiagen), and library
preparation was performed as previously described (Köser et al.
2012). Index-tagged libraries were created, and 96 separated librar-
ies were sequenced in each of eight channels using the Illumina
HiSeq platform (Illumina) to generate 100-bp paired-end reads at
the Wellcome Trust Sanger Institute. Average sequence depth
was 82.32×, and average sequence quality was 39. The ST and
CC of each isolate were determined from the sequence (Enright
et al. 2000; Cooper and Feil 2004). Sequence reads were then
mapped to relevant reference genomes based on the MLST assign-
ment to identify single-nucleotide polymorphisms (SNPs) (Harris
et al. 2010). The references genomes used were HO 5096 0412
(Köser et al. 2012) for CC 22 isolates, MRSA252 (Holden et al.
2004) for CC30 isolates, andN315 (Kuroda et al. 2001) for CC5 iso-
lates. SNPs were identified in the derived whole-genome align-
ments as previously described (Holden et al. 2013), and mobile
genetic elements, phage, and repetitive regions were excluded,
leaving a core genome size of 2,655,809
bp. Phylogenetic estimation was done
using RAxML with the general time re-
versal model and gamma correction
(Stamatakis et al. 2005). Trees were
visualized using FigTree (http://tree.bio.
ed.ac.uk/software/figtree/) and iTOL
(Letunic and Bork 2011). De novo assem-
bled multicontig draft assemblies were
generated running Velvet optimizer and
Velvet (Zerbino and Birney 2008). Con-
tigs with <300 bases were removed, and
scaffolding software SSPACE (Boetzer
et al. 2011) was employed. The assembly
was further improved using GapFiller
(Boetzer and Pirovano 2012). Antimicro-
bial susceptibility testingwas determined
by the BSAC agar dilution method
(Reynolds et al. 2008). Clustering of re-
gions was assessed on a phylogeny of
English EMRSA-15 isolates by counting
the proportion of internal nodes whose
descendants were isolated from a single
region. In order to compare this propor-
tion with the proportions expected
when isolates would be distributed ran-
domly, we randomized the leaves 1000 times and calculated the
proportions accordingly.
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